PhRMA’s Post

Name: PhRMA on LinkedIn: "Science is vital to getting new Alzheimer's therapies to market. But the…
Uploaded: 2024-06-20T14:09:19.031Z
Channel: PhRMA
Description: "Science is vital to getting new Alzheimer's therapies to market. But the public policy environment plays a critical role in whether those medicines actually ever do get to the patient." Watch more from Eli Lilly and Company's Anne White and PhRMA's Lori Reilly: https://lnkd.in/eJMDwRfE

PhRMA

57,720 followers

3mo

"Science is vital to getting new Alzheimer's therapies to market. But the public policy environment plays a critical role in whether those medicines actually ever do get to the patient." Watch more from Eli Lilly and Company's Anne White and PhRMA's Lori Reilly: https://lnkd.in/eJMDwRfE

Transcript

But so exciting is success as you know breeds support investment and that's what we need to do. But the the first step is making sure that people actually get the access to the medicines today. And that's been a little bit of a challenge in this space, especially with with Medicare. They put some additional restrictions on the space that don't exist for any other FDA approved on label indication here. And that has added another burden to what is already a complex journey. It's not easy to get diagnosed with Alzheimer's disease you do need. Several tests, several steps in the process, and unfortunately, there's additional one here because of what Medicare is applied to this particular space. Yeah, well, I'm glad she mentioned that. I think, you know, oftentimes people think about drug discovery and they think almost exclusively about the science. And, and obviously the science is vital to getting new therapies to market, but the public policy environment plays a critical role in whether those medicines actually ever do get to the patient. And we see that, obviously. The number of stages, you know, I mentioned earlier that Eli Lilly has spent, you know, over 35 years to the tune of $8 billion in the search for a treatment for Alzheimer's. That takes commitment. It also takes a public policy environment that encourages risk taking, that rewards innovation and also that understands that the ability for Lily and any other company to do that is in part dependent on the success of other medicines that Lily has developed over the years, helping to fuel that pipeline. That research and development dollars to actually keep going as I think every patient would want you to do. But we see other policies that have arisen. You mentioned the national coverage decision that was made on Alzheimer's, which is really making it even harder when we have these therapies come to market, actually get to the patients that need them, creating an in my opinion and unnecessary roadblock for medicines that we absolutely need to get. We've also seen policies such as those past in the inflation reduction. Act, which would penalize pills, medicines that are used oftentimes oral tablets that can cross the blood brain barrier, which for many conditions, we know oncology, Alzheimer's, others are really, really important. And we've now said for those medicines, we're going to create, you know, a disincentive, if you will, to bring those types of therapies to market. And so I think it's important for people to understand, yes, the science, we have to get the science right, but the public policy. Environment creates strong incentives at times in terms of bringing therapies to market, but it also unfortunately creates disincentives at times. And so as important as it is to get the medicines to market, it's equally as important that we ensure that there's access to those medicines when when they are available and that we keep the incentives there that allow companies like Eli Lilly to keep inventing.

To view or add a comment, sign in

More Relevant Posts

Juan F. González

Professor of Organic Chemistry at Universidad Complutense de Madrid
1mo
Report this post
🧠💊 Exploring New Frontiers in Alzheimer's Treatment: In our latest article, we break down how we can tackle the complexity of multi-targeted drug discovery for Alzheimer's. This approach aims to address multiple aspects of the disease simultaneously, paving the way for more effective treatments. Join us on this journey towards medical advancement! #Alzheimers #MedicalInnovation #Science https://lnkd.in/ddaGtgSg

How to address the complexity of multi-targeted drug discovery for Alzheimer’s disease?

tandfonline.com
Like Comment
To view or add a comment, sign in
Jim Tomasin

Physical Therapist/Owner at Maxim Physical Therapy
2mo
Report this post
Attention Physical Therapy professionals, a new evolution in Alzheimer's treatment is here. The FDA has approved Lilly's new drug Kisqali. It's a significant breakthrough as it targets symptoms of Alzheimer's, unlike traditional methods focusing on the cause. This could present a game changer in our operational plans. We may need to integrate this novel treatment into our holistically oriented patient service. Are we prepared or could we be overlooking valuable opportunities to enhance our patients' lives? This also has potential to recalibrate the demand for physical therapy for Alzheimer's patients. Let us reflect - are we staying ahead in this ever-changing landscape of treatments? I encourage you to reach out and explore how we might collaborate and navigate this new paradigm together in the Physical Therapy industry. #PhysicalTherapyEvolution #PatientCentricCare #NewTreatmentApproaches

1 Comment
Like Comment
To view or add a comment, sign in
Simona Stankeviciute

Vice President (Technical) at Parexel
7mo
Report this post
Designing clinical trials for Alzheimer's Disease necessitates creativity and strategic planning in evaluating product efficacy while ensuring regulatory compliance. Here I am sharing thoughts on several best practices and creative approaches to assist biotech companies in developing effective trial design strategies and planning for successful regulatory submissions. Read the full article here: https://lnkd.in/gbb8qa4q #Alzheimers #Regulatory #ParexelBiotech

Parexel

688,512 followers
7mo

Designing clinical trials for Alzheimer's Disease necessitates creativity and strategic planning in evaluating product efficacy while ensuring regulatory compliance. In the fourth edition of our neurosciences blog series, Parexel expert and former regulator, Simona Stankeviciute, M.D., shares valuable insights on several best practices and creative approaches to assist biotech companies in developing effective trial design strategies and planning for successful regulatory submissions. Is your trial set-up for global regulatory approval? Read the full article here: https://lnkd.in/gbb8qa4q #Alzheimers #Regulatory #ParexelBiotech

Discover more best practices and creative approaches for biotechs
Like Comment
To view or add a comment, sign in
Parexel

688,512 followers
7mo
Report this post
Designing clinical trials for Alzheimer's Disease necessitates creativity and strategic planning in evaluating product efficacy while ensuring regulatory compliance. In the fourth edition of our neurosciences blog series, Parexel expert and former regulator, Simona Stankeviciute, M.D., shares valuable insights on several best practices and creative approaches to assist biotech companies in developing effective trial design strategies and planning for successful regulatory submissions. Is your trial set-up for global regulatory approval? Read the full article here: https://lnkd.in/gbb8qa4q #Alzheimers #Regulatory #ParexelBiotech

Discover more best practices and creative approaches for biotechs

2 Comments
Like Comment
To view or add a comment, sign in
Prevail Therapeutics

12,279 followers
5mo
Report this post
Today, on World Parkinson's Day, we at Prevail Therapeutics pause to reflect on the journey towards empowering those affected by #ParkinsonsDisease (PD). PD presents unique challenges, impacting millions worldwide. Yet, through our dedication to research and development, we strive to redefine the possibilities for patients and caregivers alike. Our team continues to push the boundaries of science, harnessing new technologies and novel therapeutic approaches to address the complexities of PD. Prevail understands the importance of collaboration and community in combating PD. At Prevail, we're deeply committed to developing innovative solutions for those with PD. By partnering with healthcare professionals, advocacy groups, and patients themselves, we're forging a united front against Parkinson's, empowering individuals with knowledge, support, and access to advanced treatments. Together, let's continue to raise awareness, drive innovation, and inspire hope for the Parkinson’s community. To discover more about Prevail’s work with PD, visit our website: https://bit.ly/3QvAYbk #ParkinsonsAwareness #WorldParkinsonsDay
Like Comment
To view or add a comment, sign in
Chris Carles

Vice President at Healogix Research
4mo
Report this post
Eisai and Biogen's latest announcement marks a potentially transformative moment for the Alzheimer's community. After securing fast-track designation from the FDA, they have begun a rolling submission for the subcutaneous (SC) version of Leqembi (lecanemab-irmb) for weekly maintenance dosing. This development could significantly impact the Alzheimer's market, patients, and their families. On the positive side, the SC version, supported by Phase III Clarity AD study data, promises greater accessibility and convenience, allowing for at-home administration and improved reach in underserved rural areas. This could enhance the quality of life for many patients and streamline the treatment process. However, it's crucial to consider potential negative impacts as well. The transition to a new formulation may present challenges, such as ensuring consistent efficacy and managing the logistics of widespread adoption. Additionally, delays in regulatory approval and the need for further data could slow down the anticipated benefits. Explore the full article to understand how this new formulation could reshape Alzheimer’s care, while also considering the potential hurdles that lie ahead.

2 Comments
Like Comment
To view or add a comment, sign in
Naomi Angelotti

Senior Talent Acquisition Advisor- Parexel - SHRM-CP
5mo
Report this post
Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials. Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Alzheimer’s Disease vs Multiple Sclerosis Drug Development: Similarities, Differences & New Perspectives :: Parexel

share.parexel.social
Like Comment
To view or add a comment, sign in
Ana Soares

Early/Late Phase and Regulatory Strategy, RWE & RWD, Market Access, Logistics at Parexel Biotech
5mo
Report this post
Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials. Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Alzheimer’s Disease vs Multiple Sclerosis Drug Development: Similarities, Differences & New Perspectives :: Parexel

share.parexel.social
Like Comment
To view or add a comment, sign in
Lundbeck

225,719 followers
1w
Report this post
In this insightful blog, Johan Luthman, Executive Vice President, Head of R&D at Lundbeck discusses the complexities of defining unmet medical needs in drug development. He highlights the challenges of creating unbiased criteria that equally consider all disease areas, emphasizing the risk of neglecting chronic and debilitating neurological conditions like multiple system atrophy, Parkinson’s disease, or migraine. Luthman advocates for a holistic approach that integrates patient insights, scientific rationale, and societal value to ensure continued innovation and development of new treatments. Dive into the full article to explore how we can foster a sustainable ecosystem for medical advancements: https://lnkd.in/eEe_iEHv #AdvancingBrainHealth #UnmetMedicalNeeds
3 Comments
Like Comment
To view or add a comment, sign in
Natalia Dutko

Matching top talent to meaningful careers at Parexel #withheart 💜 Recruiting positions for US, Canada and EMEA
5mo
Report this post
Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials. Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Alzheimer’s Disease vs Multiple Sclerosis Drug Development: Similarities, Differences & New Perspectives :: Parexel

share.parexel.social
Like Comment
To view or add a comment, sign in

57,720 followers

View Profile Follow

PhRMA’s Post

Transcript

More Relevant Posts

Discover more best practices and creative approaches for biotechs

Discover more best practices and creative approaches for biotechs

Explore topics